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a b s t r a c t
We infected mice with the 2009 inﬂuenza A pandemic virus (H1N1pdm09), boosted with an inactivated
vaccine, and cloned immunoglobulins (Igs) from HA-speciﬁc B cells. Based on the redundancy in
germline gene utilization, we inferred that between 72–130 unique IgH VDJ and 35 different IgL VJ
combinations comprised the anti-HA recall response. The IgH VH1 and IgL VK14 variable gene families
were employed most frequently. A representative panel of antibodies were cloned and expressed to
conﬁrm reactivity with H1N1pdm09 HA. The majority of the recombinant antibodies were of high
avidity and capable of inhibiting H1N1pdm09 hemagglutination. Three of these antibodies were
subtype-speciﬁc cross-reactive, binding to the HA of A/South Carolina/1/1918(H1N1), and one further
reacted with A/swine/Iowa/15/1930(H1N1). These results help to deﬁne the genetic diversity of the
inﬂuenza anti-HA antibody repertoire proﬁle induced following infection and vaccination, which may
facilitate the development of inﬂuenza vaccines that are more protective and broadly neutralizing.
Importance: Protection against inﬂuenza viruses is mediated mainly by antibodies, and in most cases
this antibody response is narrow, only providing protection against closely related viruses. In spite of this
limited range of protection, recent ﬁndings indicate that individuals immune to one inﬂuenza virus may
contain antibodies (generally a minority of the overall response) that are more broadly reactive. These
ﬁndings have raised the possibility that inﬂuenza vaccines could induce a more broadly protective
response, reducing the need for frequent vaccine strain changes. However, interpretation of these
observations is hampered by the lack of quantitative characterization of the antibody repertoire. In this
study, we used single-cell cloning of inﬂuenza HA-speciﬁc B cells to assess the diversity and nature of the
antibody response to inﬂuenza hemagglutinin in mice. Our ﬁndings help to put bounds on the diversity
of the anti-hemagglutinin antibody response, as well as characterizing the cross-reactivity, afﬁnity, and
molecular nature of the antibody response.
& 2014 Elsevier Inc. All rights reserved.
Introduction
Inﬂuenza viruses are common pathogens of humans and animals.
In humans, inﬂuenza virus infections cause substantial morbidity
and mortality through seasonal epidemics and occasional pandemics
(Thompson et al., 2010; Molinari et al., 2007). Vaccination remains
the key component of public health protection against inﬂuenza
virus infection. However, durable protection is limited by the ability
of inﬂuenza virus to undergo rapid genetic and antigenic change,
allowing it to escape from pre-existing immunity. As a result,
inﬂuenza vaccines require updating on a regular basis (Grohskopf
et al., 2012).
Antibodies that target the principal viral surface protein, hemag-
glutinin (HA), play a major role in protection against inﬂuenza virus
infection and provide the basis for current vaccine design and the
tests by which vaccine efﬁcacy is assessed (Ellebedy and Webby,
2009). HA is a trimeric glycoprotein consisting of the membrane-
distal globular head and the stalk region. The head is responsible for
receptor binding, while the HA2 subunit is required for viral fusion
with cellular membranes. Antibodies that bind to the globular head
of HA and block receptor binding can be detected by the hemagglu-
tination inhibition (HI) assay, and HI antibody threshold titers Z32
are associated with a reduction in the risk of inﬂuenza infection (Katz
et al., 2011). There are four or ﬁve antigenic sites in the globular head
region of the HA (Caton et al., 1982; Wiley et al., 1981) and antibodies
binding to these antigenic sites generally have virus-neutralizing
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activity, but non-neutralizing globular-head binding antibodies also
have been described (Khurana et al., 2013; Daniels et al., 1987; Laeeq
et al., 1997; Temoltzin-Palacios and Thomas, 1994; Yewdell et al.,
1986). Antibodies binding outside these antigenic sites, including to
the stalk region of HA, have also been identiﬁed. Some of these
antibodies confer protection against infection, either by directly
blocking virus infectivity or by playing a role in other functions
of the immune system, such as antibody-dependent cellular
cytotoxicity (ADCC)-mediated activation of NK cells (Jegaskanda
et al., 2013a,b; Srivastava et al., 2013) or complement (Co et al.,
2012; Terajima et al., 2011).
Inﬂuenza virus can tolerate signiﬁcant sequence variation in
antigenic sites, and sequence changes in these regions (“antigenic
drift”) often reduce binding of the existing antibody repertoire.
Some anti-HA antibodies, however, are broadly cross-reactive, and
can confer protection to a range of viruses within a particular HA
subtype or even across subtypes. These antibodies have been
reported to bind to conserved regions within the globular head
of HA (Corti et al., 2010; Wrammert et al., 2011; Yoshida et al.,
2009; Whittle et al., 2011; Ekiert et al., 2012) or the stalk region
(Corti et al., 2010, 2011; Wrammert et al., 2011; Okuno et al., 1993;
Throsby et al., 2008; Sui et al., 2009; Ekiert et al., 2011; Dreyfus
et al., 2012).
Clearly the goal of inﬂuenza vaccination is to increase the
proportion of antibodies that are protective, and ideally to increase
the proportion that are cross-protective against multiple strains.
Generating antibodies after vaccination that are cross-protective
against antigenically drifted strains of the same subtype may
reduce the need for frequent updates of vaccine strains. Further-
more, a vaccine that could elicit broadly cross-reactive antibodies
that protect against multiple subtypes of HA would be an impor-
tant public health tool in the event of a newly emerged virus with
pandemic potential. However, without understanding the relative
frequency of strain-speciﬁc versus cross-reactive, it is difﬁcult to
preferentially stimulate an optimal antibody response.
Evaluating the anti-inﬂuenza repertoire in humans is complicated
by the fact that, with increasing age, individuals are repeatedly
exposed to antigenically diverse inﬂuenza viruses, including both
different subtypes and drifted strains within a subtype. Exposure to
any particular HA is likely to preferentially stimulate and expand
previously primed B cells, eclipsing the stimulation of naive B cells
and thereby potentially impairing the generation of strain-speciﬁc,
high-afﬁnity antibodies that provide a more protective response.
At the molecular level, mouse antibody responses are generally
similar to that of humans, but the exposure of laboratory mice to
inﬂuenza viruses can be controlled. To understand the antibody
repertoire arising from infection with inﬂuenza virus, we infected
naïve C57BL/6 mice with the 2009 pandemic inﬂuenza A virus
(H1N1pdm09) and boosted them with an inactivated inﬂuenza
vaccine. B cells speciﬁc to HA were puriﬁed, and the immunoglo-
bulin (Ig) heavy and light chain variable regions were cloned from
single B cells to characterize the diversity and speciﬁcity of the
anti-HA antibody repertoire.
Results
Anti-HA B cell identiﬁcation and puriﬁcation
To induce an anti-HA response, C57BL/6 mice were administered
a sub-lethal infection with OH/07(H1pdm), and 3 weeks later, the
mice were boosted with 2011/2012 TIV. Three days post-boost,
spleens from four mice were harvested and pooled. Antigen-
positive B cells (1.5–8% of the CD19/IgM-population: Fig. 1D vs.
Fig. 1B) were single cell-sorted onto glass slides based on their ability
to bind CA/04(H1pdm) recHA. As a control, lymphocytes were
stained with the distantly related recHA of DE/68(H13) (Fig. 1A
and C).
Anti-HA IgH and IgL gene segment usage
The ampliﬁcation of the IgH gene from the single cells yielded
54 heavy chains for which respective VDJH germline genes were
identiﬁed according to the international ImMunoGeneTics data-
base (IMGT) (Lefranc et al., 2009). In total, genes representing 4 of
the 15 murine VH families were identiﬁed (Fig. 2A). The VH chains
displayed a strong bias toward the use of the VH1 family (74%),
which represents approximately 50% of the VH gene repertoire
available and is located most distal from the diversity genes
(Schroeder, 2006; de Bono et al., 2004; Johnston et al., 2006).
Within the four VH families, the VH genes included 14 of the
possible 92 functional C57BL/6 VH genes (de Bono et al., 2004), of
which IGHV1-82n01 was the most common (26%), followed by
IGHV5-4n01 (13%) (Fig. 2B). The DH segment of IgH most fre-
quently employed was the DH1-1n01 gene (37%) (Fig. 2C). For the
JH gene segment, genes 1–4 were used with similar frequencies,
ranging from 20 to 30% each (Fig. 2D).
Because C57BL/6 mice predominately use the kappa light chain
(Schroeder, 2006), and preliminary experiments conﬁrmed that
the anti-HA response in our experiments was composed of 85–90%
kappa light chain usage (data not shown), we only ampliﬁed these VL
chains. Of the 18 known VK families, 10 (55.5%) were identiﬁed in our
screen with a bias toward the use of the VK14 family (36%) (Fig. 2E).
VK3 and 4 were also well represented, with 24% and 16% of germline
sequences used, respectively. Of the possible 93 murine-expressed VK
genes, 19 were recovered from the HA-speciﬁc B cells (20%) (Fig. 2F),
and of these, segment IGKV14-130n01 was obtained most frequently
(26%), followed by IGKV3-4n01 and 14-11n01 (10% each). All four
possible IgL J genes were used, with JK5 represented most often
(44%) (Fig. 2G).
Germline gene combinations and CDR3 sequence analysis of the IgH
and IgL chain anti-HA repertoire
The 54 individual anti-HA IgH chains included 32 distinct VDJH
combinations, with 11 being employed multiple times (from 2 to
6 times) (Fig. 3A). The length of the CDR3 region (produced through
joining the 30 end of VH, a D segment, and the 50 end of JH) ranged
from 8 to 17 amino acids (Fig. 3B). As well as a number of identical
CDR3 sequences, clusters of similar CDR3 sequences were observed,
mainly but not solely driven by similar VDJ usage (Fig. 3A). For
example, the sequence C[T/A][T/S]GGSSGYGGAYW was seen ﬁve
times, and was generated by the use of the same V, D, and J gene
segments (14-4n01, 3-2n02, and 3n01 respectively), while the
sequence CVRRGDYYFDYW, identiﬁed twice, was generated from
either 1-50n01/1-1n02/3n01 or 1-50n01/1-3n01/2n01 V/D/J regions.
The 50 IgL chains encode 25 unique VJL combinations, 12 of
which were represented multiple times (from 2 to 9 instances)
(Fig. 3C). For IgL, the CDR3 region is formed by the 30 end of VL and
the 50 end of JL. The length of the IgL CDR3 ranged from 8 to 11
amino acids, with 90% encoding nine residues (Fig. 3D). The VL
CDR3 sequences were less diverse than those of VH, with three
major clusters identiﬁed, including nine that had identical
sequences (Fig. 3C). As with IgH, some evidence for convergence
on sets of CDR3 sequences was observed. Similar CDR3 sequences
were usually generated by identical V/J germline usage (e.g., nine
instances of CLQFYEFPLTF generated by 14-130-01/5n01), but in
some cases, similar CDR3 sequences were generated by different
V and J germlines (CQQS[K/N]E[V/D]P[L/W]TF generated by
3-2n01/5n01 or 3-4n01/1n01).
In 18 cases we ampliﬁed both the IgH and IgL chain from the
same B cell, allowing analysis of the complete antibody gene
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segment utilization (Table 2), as well as the cloning of an rmAb for
functional analysis. In some cases (e.g., 146-D11 and 146-C07), the
use of a similar IgH sequence (CDR3: CT[T/S]GGSSGYGGAYW, V/D/
J: 14-4n01/3-2n02/3n01) and an identical light chain (CDR3:
CQQWSSNPPTF,V/J: 4-59n01/2n01) suggests that these samples
may represent clonal expansion and somatic mutation of a single
naïve B cell. However, rmAb 046-D11, with the same IgH CDR3 and
V/D/J usage as 146-D11 and 146-C07, was paired with a different
light chain (CDR3 sequence CLQFYEFPLTF, 14-130-01/5n01 V/J).
Similarly, within IgL sequences, the IGKV14-130n01/IgJ5n01 com-
bination was seen most often (18% of sequences: Fig. 3C), but of
the three rmAb with this IgL sequence (046-D11, 069-A09, and
139-22a: Fig. 3C and Table 2), each was paired with a different IgH,
showing that these were not produced by clonal expansion and
again supporting the notion of convergence upon a common
paratope.
Diversity of the anti-HA antibody response
Our sample contained 32 different VDJ sequences among 54 total
heavy chain sequences, and 25 different VJ sequences among 50 total
light chain sequences. We used several approaches (Burnham
and Overton, 1978, 1979; Chao, 1984; Chao and Lee, 1992; Chao and
Bunge, 2002; Wang and Lindsay, 2005; Wang, 2010, 2011) to
predict the overall germline sequence diversity within the anti-HA
immunoglobulin response, based on the numbers of repeated
(“recaptured”) sequences in our sample. The algorithms consistently
inferred that our sample drew from a pool of 72–130 different
heavy chain VDJ combinations, and 35 light chain VJ combinations
(Table 3).
Generation of mouse–human chimeric antibodies
In 18 cases, we cloned both an IgH and an IgL variable region
from the same individual B cell (Table 2). All except two (146-C07
and 146-D11) were unique in terms of germline IgH and IgL
combinations. When sorting single B cells by ﬂow cytometry, we
selected IgG-expressing rather than IgM-expressing cells. Since
this population has undergone class switching, they should be
dominated by memory cells and likely contain some level of
somatic mutation in the IgH and IgL regions. Varying levels of
somatic mutation, at the amino acid level, were present in these
genes (0–15 mutations for H and 0–8 for L) (Table 2, “Δ”). Only one
rmAb (065-C06) retained germline sequence in both IgH and IgL,
indicating that as expected most antibodies had undergone some
amount of afﬁnity maturation during the infection and
vaccine boost.
The matched IgH and IgL chains were cloned into a vector
supplying an IgG1 human constant region (heavy chain) or human
kappa constant region (light 4chain), as well as the IL2 signal
sequence and promoter elements to allow expression in mamma-
lian cells. For 16 of the pairs, co-expression of the IgH and IgL
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Fig. 1. Flow cytometry of splenocytes from mice immunized with H1pdm. C57BL/6 mice were immunized with H1N1pdm09 virus and boosted with TIV as described.
Splenocytes from naïve mice (A,B) or immunized mice (C,D) were stained with a cocktail of antibodies including CD19, and with H13 as a control (A,C) or H1pdm (B,D).
Splenocytes were gated as described to show the percent of HA-speciﬁc B cells.
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Fig. 2. IgH and IgL germline usage. HA-speciﬁc B cells were sorted and IgH and IgL variable regions were ampliﬁed from individual B cells and sequenced. Germline usage
was determined using the international ImMunoGeneTics database of mouse immunoglobulin sequences. The usage of VH gene families (A), VH genes (B), DH genes (C),
JH genes (D), VK gene families (E), VK genes (F) and JK genes (G) are shown as a percentage of total heavy or light chain sequences respectively.
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chains in 293T cells resulted in secretion of recombinant mono-
clonal antibodies (rmAb), which migrated at approximately
150 kDa when subjected to SDS-PAGE, the same size as a control
Ig (data not shown). Two of the antibody IgH/IgL pairs (065-C09
and 065-D10) did not efﬁciently assemble into full-sized mature
Ig, and predominately showed bands of an apparent molecular
mass of 50 and 25 kDa (data not shown); therefore, these pairs
were not analyzed further. The concentration of each rmAb was
determined by ELISA and normalized by concentrating the tissue-
culture supernatant to approximately 25 mg/mL.
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Fig. 3. IgH V/D/J and IgL V/J gene combinations and CDR3 sequences. CDR3 sequences were aligned using MUSCLE (Edgar, 2004) and a maximum likelihood dendrogramwas
generated using MEGA5 for IgH (A) and IgL (C). Columns indicate the IgH or IgL identiﬁer (“ID”), the CDR3 sequence (CDR3), and the identity of the V, D, and J (IgH) or V and J
(IgL) gene segments used. “n” indicates the segment was sequenced but not cloned. The overall distribution of IgH (B) and IgL (D) CDR3 length.
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Most cloned Igs recognize inﬂuenza hemagglutinin
The 16 rmAb were screened for reactivity by ELISA using the
2011/12 TIV as an antigen. In total, 15 of the rmAb reacted with
TIV (deﬁned as a signal greater than twice background level, at
r25 mg/mL), and 10 of these bound at a concentration of o1 μg/
mL (Table 4), indicating that the sorting process isolated B cells
that do in fact target HA.
The rmAb were further characterized by ELISA for reactivity to
the individual viruses that were components of the TIV. Eleven of
the rmAb were reactive with the monovalent vaccine containing
the HA from CA/07(H1pdm), while none reacted with inactivated
BR/60(B) (Table 4). Four rmAb were also reactive with inactivated
VIC/210(H3), although for three rmAb (145-D11, 146-B09 and 146-
D11) this reactivity was only seen at the highest concentration
tested. The fourth rmAb (065-C11) was strongly reactive with
VIC/210(H3) as well as CA/07 (H1pdm) (Table 4), suggesting that it
is a subtype cross-reactive antibody.
Cloned Igs recognize H1 with high afﬁnity
BioLayer interferometry (BLI) was performed on the 11 rmAb
with the highest binding activity toward H1N1pdm by ELISA
analysis, to determine the relative binding rate constants to recHA
of CA/07(H1pdm). Two rmAb (065-C11 and 069-B03) did not bind
detectably bind recHA in this assay, while the nine remaining
rmAb bound recHA with similar association rates, surpassing that
of the control Ab (Fig. 4A). These nine rmAb can be divided into
two categories based on dissociation rates: those ranging from
8106(1/s) to 3.7105(1/s) (065-C05, 065-D01, 139-22a,
145-C09, 145-D11, 146-C07 and 146-D11) and a second with faster
dissociation rates ranging from 4.9105(1/s) to 1.4104(1/s)
(069-A09, 145-C09 and 146-B09) (Fig. 4B). As the rmAb association
rates were similar, each group also has similar steady state
afﬁnities, of about 21011 to 6.41011 KD for the ﬁrst group
and 7.81010 to 2.6109 KD for the second group (Fig. 4C).
Interestingly, 065-C11, an antibody that displayed strong reactivity
with the TIV as well as with the individual H1N1pdm and H3N2
virus components of the TIV in ELISA (Table 4), failed to detectably
bind to recombinant H1pdm in this assay.
Cloned Igs are able to inhibit hemagglutination
We also tested the ability of the 16 rmAb to block hemagglu-
tination of the TIV constituent viruses individually. The HI assay is
widely used to measure inﬂuenza post-infection and post-
vaccination antibody responses that are biologically meaningful,
since HI titers Z32 or 40 are correlated with protection against
inﬂuenza infection (Katz et al., 2011). All nine rmAb that were
strongly reactive in the recHA BLI assay also showed HI activity
against the CA/07(H1pdm) virus at concentrations ranging from
0.098 to 0.78 mg/mL (Table 4). Only 145-D11, a rmAb that was
weakly reactive with VIC/210(H3) by ELISA showed HI activity
against VIC/210(H3) virus, and then only at 12.5 mg/ml. 065-C11,
which showed binding activity toward TIV in ELISA assays
Table 1
Viruses and recombinant proteins used in this study. recHA, recombinant hemagglutinin. TIV, trivalent inactivated vaccine. MIV, monovalent inactivated vaccine.
Strain Abbreviation Subtype Group HA accession # HA (HA1) % AA
identity to OH/07
Comment
A/Ohio/07/2009 OH/07(H1pdm) H1N1pdm09 1 ACQ76386.2 100 Wild-type virus for mouse infection
A/California/04/2009 CA/04(H1pdm) H1N1pdm09 1 ACP41105.1 99 (98) recHA/FACS bait/ELISA antigen
A/California/04/2009 CA/04(HA1pdm) H1N1pdm09 1 (98) recHA/ELISA antigen
A/California/07/2009 CA/07(H1pdm) H1N1pdm09 1 AFM72832.1 99 (98) TIV component/ELISA antigen/HI,
recHA/ForteBio
A/Shorebird/Delaware/68/2004 DE/68(H13) H13N9 1 ABB87334.1 50 (45) recHA/FACS bait/ELISA antigen
A/Victoria/210/2009(H3N2) VIC/210(H3) H3N2 2 AFM72894.1 43 (36) TIV component/ELISA antigen/HI
B/Brisbane/60/2008 BR/60(B) B (Victoria lineage) – ADN32817.1 28 (22) TIV component/ELISA antigen/HI
A/South Carolina/1/1918 SC/1918(H1) H1N1 1 EPI15571 86 (83) recHA/ELISA antigen
A/swine/Iowa/15/1930 IA/1930(H1) H1N1 1 AF091308.1 86 (83) recHA/ELISA antigen
A/Brisbane/59/2007 BR/59(H1) H1N1 1 EPI162496 80 (73) recHA/ELISA antigen
Table 2
rmAb germline gene usage and number of mutations. For eighteen individual B
cells, both heavy and light chain variable sequences were sequenced. The germline
usage for VDJ and VJ (VH/VL) genes was deﬁned using the IMGT database. The
number of amino acid mutations (“Δ”) was identiﬁed by comparison of the
germline sequence to the amino acid sequence of the respective genes.
rmAb VH DH JH Δ VL JL Δ
046-D02 1-42n01 1-1n01 4n01 3 14-130n01 4n01 3
046-D11 14-4n01 3-2n02 3n01 9 14-130n01 5n01 4
065-C05 1-53n01 2-2n01 4n01 4 4-59n01 1n01 2
065-C06 3-6n01 2-3n01 1n03 0 3-4n01 1n01 0
065-C09 1-67n01 2-12n01 4n01 11 10-94n01 4n01 6
065-C11 1-22n01 2-3n01 2n01 7 3-4n01 1n01 3
065-D01 1-82n01 2-4n01 1n01 6 14-111n01 5n01 3
065-D10 5-2n01 2-4n01 2n01 7 14-111n01 5n01 8
069-A09 1-50n01 2-10n02 2n01 7 14-130n01 5n01 1
069-B03 1-82n01 1-1n01 4n01 4 3-4n01 2n01 4
069-B05 1-15n01 1-1n01 4n01 8 4-55n01 2n01 1
139-22a 1-69n01 2-5n01 3n01 15 14-130n01 5n01 1
139-23b 1-82n01 2-4n01 1n03 10 14-111n01 5n01 3
145-C09 5-4n01 1-1n01 2n01 5 3-2n01 5n01 0
145-D11 1-82n01 2-4n01 2n01 2 4-57n01 3n01 4
146-B09 1-80n01 1-1n01 4n01 7 6-23n01 5n01 5
146-C07 14-4n01 3-2n02 3n01 6 4-59n01 2n01 3
146-D11 14-4n01 3-2n02 3n01 4 4-59n01 2n01 4
Table 3
IgH and IgL diversity estimates: The “SPECIES” module for R was used to estimate
the diversity of the combinations of germline V, D, and J segments (IgH chain) or V
and J segments (light chain) in the population of antibodies speciﬁc for HA, based
on sampled IgH and IgL sequences. Estimates and 95% conﬁdence intervals (CI) are
shown for each method.
VDJ (H) VJ (L) Reference
Estimate 95% CI Estimate 95% CI
113 55–321 35 29–60 Chao (1984)
75 47–148 38 30–60 Chao and Lee (1992) (ACE method)
92 51–223 38 29–63 Chao and Lee (1992) (ACE-1 method)
72 40–171 35 28–60 Chao and Bunge (2002)
111 63–159 39 29–49 Burnham and Overton (1978, 1979)
129 47–251 38 28–80 Wang and Lindsay (2005)
97 63–114 37 32–71 Wang (2010)
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(Table 4) but no reactivity to the recHA in BLI (Fig. 4), also lacked
HI reactivity. All rmAb failed to inhibit hemagglutination of BR/60
(B) (Table 4).
ELISA activity against H1N1 recHA's
Having established that the panel of rmAb displays only limited
cross-clade reactivity, we further tested the ability of the 11 rmAb
reactive to the H1pdm vaccine component (Table 4) to bind a set of
recHA within the H1 lineage. The amino acid identities of each HA,
compared to OH/07, are shown in Table 1, and range from 80%
(BR/59) to 86% (SC/1918 and IA/1930). As a control we also
included HA from the H13 lineage (DE/68).
All but 065-C11 bound to the full-length recHA from CA/04
(H1pdm). Consistent with the HI activity of these rmAb, the same
rmAb also bound to the HA1 domain of CA/04. Three rmAb (065-D01,
069-A09 and 139-22a) also showed reactivity with the recHA of
SC/1918, at levels comparable to that of CA/04 (Table 5).
065-D01 further reacted with the recHA of IA/1930, although at
4200-fold increased concentration. None of the rmAb bound detec-
tably to recHA from Bris/59. The rmAb 065-C11, which efﬁciently
bound to both H1N1pdm09 and H3N2 vaccine antigen but failed to
bind recHA in BLI analysis, also failed to bind recHA in the more
sensitive ELISA assay. This suggests the 065-C11 rmAbmay recognize a
cross-reactive conformational epitope present in virus-associated HA
that is not preserved in the recHA used for ELISA assays.
Discussion
The antibody response to HA following inﬂuenza virus infection or
vaccination includes a wide range of speciﬁcities. Some antibodies
bind to highly strain-speciﬁc regions and confer protection, others
bind to conserved regions that can lead to varying degrees of cross-
reactive protection, and somemay bind to HAwithout neutralizing the
virus in vitro, although in some cases (though not all, Khurana et al.,
2013; To et al., 2012) such antibodies may confer some protection
in vivo (McLain and Dimmock, 1989). Although antibodies with these
different speciﬁcities and functions can be measured using different
assays (e.g. ELISA, microneutralization (MN), and HI), the relative
proportion of antibodies with each type of speciﬁcity and function
that is stimulated by a given exposure event is unclear. In this study,
we isolated mouse memory B cells speciﬁc to inﬂuenza H1pdm HA,
analyzed individual IgH and IgL genes to characterize the genetic
diversity of the response, and produced recombinant antibodies to
analyze speciﬁcity and binding kinetics. Although there are some
molecular differences between mouse and human antibodies, in
general the B cell response is similar in the two species. Because
humans are typically repeatedly exposed to multiple strains of
inﬂuenza throughout their lifetime, leading to unpredictable expan-
sion of particular B cell clones depending on the precise history of
virus exposure, the mouse is a simpler model that can be used to
assess antibody responses to the virus.
Overall, the anti-HA antibody response generated in these mice
was relatively constrained. The 54 heavy chain variable genes analyzed
in our sample included 14 different VH genes (representing four
different families), while the 50 light chain variable regions included
19 different VK genes from 10 different families. We infer that our
samples drew from a population of approximately 72–130 different
heavy chain VDJ combinations, and approximately 35 different light
chain VJ combinations. This suggests that there must be considerable
redundancy in the germline usage for the anti-HA response, as
previously proposed based on the studies of anti-HA monoclonal
antibody repertoire (Caton et al., 1991; Staudt and Gerhard, 1983). This
inference assumes that the puriﬁcation of the HA-speciﬁc B cells and
cloning of variable regions was unbiased, and that relevant anti-HA
antibodies raised against virion-associated HA will bind to recombi-
nant HA. However, while it is difﬁcult to validate this without already
knowing the global anti-HA repertoire, sorting was performed using
the full HA ectodomain and PCR primers covered the full range of
heavy and kappa light chain sequences, so there is no a priori reason
to expect bias. Considering the further diversity contributed by heavy/
light chain pairing, junctional diversity, and somatic hypermutation,
the actual pool of H1pdm anti-HA antibody repertoire must be
signiﬁcantly larger than these estimates, roughly consistent with the
BALB/c PR8 anti-HA paratypic repertoire of approximately 1500
speciﬁcities estimated by Staudt and Gerhard (1983).
CDR3 regions are generally a principal determinant in antigen
molecule binding speciﬁcity (Davis et al., 1997; Xu and Davis, 2000).
IgH chain CDR3 sequences showed some redundancy, while the IgL
CDR3 repertoire was less diverse, suggesting that a limited number of
CDR3 sequences (especially in IgL) are preferred for binding to H1pdm
Table 4
Binding of rmAb to inactivated vaccines and hemagglutination inhibition assays. rmAb produced as described were screened by ELISA for reactivity with TIV (containing
CA/07(H1pdm), VIC/210(H3), and BR/60(B)) and with the individual monovalent inactivated vaccine (MIV) constituents: CA/07(H1pdm), VIC/210(H3), and BR/60(B). Data are
shown as minimum rmAb concentration (ng/ml) required to produce a 2-fold signal above negative control. “-“, no reactivity seen at concentrations ≤25 µg/mL. “NT”, not
tested. rmAb were also tested in HI assays against CA/07(H1pdm), VIC/210(H3), and B/BR/60. Values are shown as minimum concentration (ng/mL) rmAb required to inhibit
4 HA units of antigen. “*“, no HI activity seen at concentrations ≤12.5 µg/mL.
rmAb ELISA titer HI titer
TIV CA/07 (H1pdm) VIC/210 (H3) BR/60 (B) CA/07 (H1pdm) VIC/210 (H3) BR/60 (B)
046-D02 – – NT NT n n n
046-D11 1390 – – – n n n
065-C05 1.9 1.14 – – 780 n n
065-C06 25,000 – NT NT n n n
065-C11 50 3.43 5.7 – n n n
065-D01 5.7 3.43 – – 98 n n
069-A09 930 30.86 – – 98 n n
069-B03 25,000 25,000 – – n n n
069-B05 25,000 – NT NT n n n
139-22a 1.9 1.14 – – 98 n n
139-23b 25,000 – NT NT n n n
145-C09 150 3.43 – – 780 n n
145-D11 1.9 3.43 25,000 – 98 12,500 n
146-B09 5.7 1.14 25,000 – 49 n n
146-C07 1.9 1.14 – – 98 n n
146-D11 1.9 1.14 25,000 – 98 n n
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HA. The fact that very similar CDR3 sequences were generated from
different IgH V/D/J IgL V/J combinations also suggests convergence on
a speciﬁc set of CDR3 sequences. The lower diversity seen in the IgL
germline usage and CDR3 sequences compared to IgH (Fig. 3A vs.
Fig. 3C) may imply that the IgL region is more important than the IgH
region in determining binding speciﬁcity, and is therefore more
constrained.
The analysis of 16 paired IgH/IgL chains, each derived from
a single B cell (i.e. variable regions from the natural antibody),
indicated that the majority of these Igs (15 out of 16) were indeed
speciﬁc to the boosting antigen, in that they were capable of
binding TIV in ELISA assays. Of these, 10 rmAb bound to inacti-
vated CA/07 at low concentrations (o31 ng/mL), and nine bound
recHA with high afﬁnity (4109 K). However, these assays may
underestimate HA binding to B cells because previous studies
have shown that B cell Igs that are capable of binding HA when
expressed on the surface of a B cell (as membrane-bound molecules)
may have low afﬁnity or fail to bind to HAwhen expressed as secreted
antibodies in the germline form (Lingwood et al., 2012). In particular,
this may explain the poor binding activity of 065-C06, a rmAb that
maintained strictly germline identity. This rmAb, as a soluble human/
mouse chimeric molecule, bound TIV only at the highest concentration
tested by ELISA. In addition, it is possible that the use of human
constant regions for these mouse variable regions may have led to
some changes in activity. For example, two of the cloned IgH/IgL pairs
failed to assemble when expressed in the context of the human
constant regions (Table 2 and data not shown), even though they were
derived from a single B cell and presumably capable of effective
assembly in vivo.
As well as binding to inactivated virus, 9 of the 16 rmAb bound
recHA1 (the globular head of HA) and were active in HI assays.
Thus, 450% of the cloned antibodies have the ability to inhibit
virus receptor binding, a function of neutralizing and protective
antibodies (Katz et al., 2011).
Three rmAb further showed subtype-speciﬁc cross-reactivity
with the antigenically related recHA of SC/1918, and one also
reacted weakly with IA/30; none reacted with the recent seasonal
H1N1 virus BR/59. These viruses share just 73–83% identity to OH/
07 in the HA1 region; however, speciﬁc antigenic sites are more
similar. For example, the Sa region of SC/1918 is 92% identical to
OH/07, and previous studies have identiﬁed cross-reactive anti-
bodies isolated from humans that target this region (Krause et al.,
2010). Four of the antibodies showed some cross-reactivity with
H3N2, although three of these reacted only weakly. One of these
also had HI activity against H3N2, although again, this activity was
only detected at high concentrations. This is not surprising as the B
cells were sorted based on the ability to bind recHA of H1pdm,
which shares only 43% AA identity with HA of VIC/210. Further, a
lack of H3 HA cross-reactivity is likely due to the timing of
splenocyte harvest (day 3 post TIV boost). Interestingly, the rmAb
with the most cross-reactivity in ELISA using inactivated vaccine
(Table 4, 065-C11) did not show detectable HI activity against any
virus, or did it react with recHA in BLI or ELISA assays. This rmAb
failed to react with the distantly related inﬂuenza B virus,
suggesting that the broad inﬂuenza A cross-reactivity is speciﬁc.
These ﬁndings suggest that 065-C11 may react with a conserved,
conformationally sensitive epitope on HA and future experiments
will aim to identify this interaction. Thus, although some cross-
subtype reactivity was identiﬁed in our characterization, the cross-
reactivity was weak and poorly associated with HI activity.
In conclusion, these ﬁndings suggest that the antibody recall
response to HA following H1N1pdm infection and vaccination
of naïve animals is diverse, but based on a relatively limited number
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Fig. 4. Biolayer interferometry analysis of binding kinetics. BioLayer Interferometry
(BLI) using an Octet Red instrument (Fortebio) was performed as described. The
association rate (Kon) (A), dissociation rate (Kdis) (B), and the steady state afﬁnity
(KD) (C) were calculated for each rmAb. Error bars represent the standard deviation
generated by running multiple rmAb concentrations.
Table 5
Binding of rmAb to H1N1 recHA. rmAb were screened by ELISA for reactivity with
the respective recHA. Data are shown as minimum rmAb concentration (ng/ml)
required to produce a 2-fold signal above negative control. “-“, no reactivity seen at
concentrations ≤12.5 µg/mL.
rmAb recHA
CA/04
(H1pdm)
CA/04
(HA1pdm)
SC/1918
(H1)
IA/1930
(H1)
Bris/59
(H1)
DE/68
(H13)
065-C05 1.9 1.9 – – – –
065-C11 – – – – – –
065-D01 1.9 1.9 5.7 463 – –
069-A09 1.9 1.9 51 – – –
069-B03 12,500 12,500 – – – –
139-22a 1.9 0.635 3 – – –
145-C09 1.9 0.57 – – – –
145-D11 1.9 1.9 – – – –
146-B09 460 150 – – – –
146-C07 0.635 1.9 – – – –
146-D11 0.635 1.9 – – – –
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of germline sequences. The majority of cloned antibodies are directed
against the globular head of HA and exhibited HI activity and are
therefore likely capable of protecting against inﬂuenza disease in vivo.
A subset of these antibodies further showed subtype-speciﬁc cross-
reactivity with the antigenically related recHA of SC/1918 while
minimal subtype cross-reactivity was identiﬁed. Further studies with
this approach will help to delimit the diversity of the antibody
repertoire proﬁle in response to novel vaccination strategies, with
the goal of identifying approaches that induce a high yield of broadly
reactive and neutralizing antibodies.
Materials and methods
Cells, virus, and recombinant hemagglutinin
Human embryonic kidney 293T cells (293T) were obtained
from ATCC (Manassas, VA) and maintained in Dulbecco's modiﬁed
Eagle's medium (DMEM) supplemented with 10% fetal calf serum
(Thermo Fisher Scientiﬁc, Pittsburg, PA) and penicillin streptomy-
cin (Invitrogen, Carlsbad, CA).
Inﬂuenza viruses were grown in embryonated chicken eggs and
titers were determined on MDCK cells by plaque assay. Table 1
summarizes the viruses and recHAs used, including the abbrevia-
tions used in this report.
The full-length recombinant his-tagged HA (recHA) from CA/04
(H1pdm) and DE/68(H13) used for ﬂuorescence-activated cell
sorting (FACS) analysis were obtained from the Inﬂuenza Reagent
Resource (IRR) (Manassas, VA). For ELISA studies, full-length recHA
from CA/04(H1pdm), SC/1918(H1), IA/1930(H1) and Bris/59(H1)
were also obtained from IRR (Manassas, VA). For kinetic studies,
the CA/07(H1pdm) recHA protein was produced in a baculovirus
expression system as previously described (Yang et al., 2010).
Inoculation of mice and isolation of leukocytes
All animal experiments were performed in accordance with the
guidelines of the CDC Institutional Animal Care and Use Committee in
an Association for the Assessment and Accreditation of Laboratory
Animal Care accredited facility. Female 8–12 week old C57BL/6 mice
were anesthetized by isoﬂurane inhalation and inoculated intranasally
with 50 mL containing 104–105 plaque-forming units of OH/07
(H1pdm) diluted in sterile PBS, pH 7.4. Three to four weeks post-
infection, mice were boosted by IP injection with 200 mL of the 2011/
12 trivalent inactivated inﬂuenza vaccine (TIV) (Fluarix: GSK, Research
Triangle Park, NC), which contained the HA from CA/07(H1pdm), VIC/
210(H3), and BR/60(B) viruses (6 mg of each HA). Three days post-
boost, four mice per group were euthanized by isoﬂurane overdose
followed by cervical dislocation, and spleens were harvested and
pooled in order to remove inter-individual bias. In brief, the spleens
were ground between two frosted glass slides, and the cells were
dissociated through a 70-μm mesh strainer. Cells were then centri-
fuged at 550  g for 20 min over an 18.23% histodenz (Sigma-Aldrich,
St Louis, MO) cushion at room temperature with the brake off. The
low-density cells were collected, washed with FACS buffer and
incubated in red blood cell lysing media (Sigma-Aldrich) for 5 min at
room temperature. The cells were again washed and resuspended in
FACS buffer for further analysis.
Biotinylation of recHA
CA/04(H1pdm) and DE/68(H13) recHA (2 mg of each) were
buffer exchanged into 0.1 M sodium acetate, pH 5.5 (oxidation
buffer), by centrifugation in Amicon Ultra-4 desalting centrifugal
ﬁlter units (Millipore, Billerica, MA) and diluted to a ﬁnal volume
of 1 ml (2 mg/ml). The glycans on the proteins were oxidized by
adding 1 ml of 20 mM sodium meta-periodate (Sigma-Aldrich)
and incubating for 30 min on ice, in the dark. The buffer was then
exchanged to PBS, pH 7.2, in a total volume of 3.6 ml, using a
desalting column. Four hundred microliter of 50 mM Pierce Biotin-
PEG4-Hydrazide in DMSO (Thermo Fisher Scientiﬁc) was added to
the protein, which was then incubated for 2 h at room tempera-
ture with gentle rocking, protected from light. The protein was
again buffer exchanged into 50 mM Tris-Cl, pH 7.4 containing
100 mM NaCl and 15% w/v glycerol. The concentration of the
protein was determined using the Coomassie Plus Protein Assay
Reagent (Thermo Fisher Scientiﬁc), and the molar ratio of biotin to
protein was quantiﬁed using the Pierce Biotin Quantitation Kit
(Thermo Fisher Scientiﬁc). The protein was stored at 80 1C in
single-use aliquots.
B cell labeling and ﬂow cytometry
The isolated leukocytes were labeled with biotinylated HA,
followed by streptavidin-APC (BD Biosciences). In addition, the
following surface markers were used: CD3e-V450 (500A2), CD4-
V450 (RM4-5), CD8a-V450 (53-6.7), CD11b-V450 (M1/70), IgD-
V450 (11-26c.2a), Gr1-V450 (RB6-8C5), CD19-PE-Cy7 (1D3),
CD138-PE (281-2) and IgM-FITC (R6-60.2) (BD Biosciences, San
Jose, CA). All staining was performed in the following antibody
dilution buffer: Hank's Balanced Salt Solution (HBSS) containing
5% FBS (Hyclone), 10 mM of EDTA, 10 mM of HEPES, 1% Fc Block
(BD Biosciences, San Jose, CA) and 5% each of normal hamster
serum, normal mouse serum and normal rat serum (Jackson
ImmunoResearch). The optimal staining conditions identiﬁed were
5 mg/ml of biotinylated-HA and 1.25 mg/ml of streptavidin-APC.
Cells were analyzed using a BD FACS CANTO II, and single cell
sorting was performed using a BD FACS Aria II. The cells were
gated on FSC-A/FSC-H to remove doublets and FSC-A/SSC-A to
remove debris. Single antigen-positive B cells were sorted based
on IgM-/CD19þ/HAþ surface staining onto the 48 reaction sites
of an AmpliGrid AG480F slide (Beckman Coulter, Houston, TX).
A visual analysis of cell deposition on the AmpliGrid AG480F slide
using a microscope was used to monitor the accuracy of the sort.
Molecular cloning of Ig genes
A multiplex one-step RT-PCR (Qiagen, Valencia, CA) was per-
formed directly on the slide in a 1 mL reaction containing 1
Qiagen RT-PCR buffer, 0.6 pmol of primer mix, 0.4 mM of each
dNTP, 0.8 U of RNAsin and 0.04 mL of Qiagen enzyme mix. The
primer mix was adopted from Tiller et al. with slight modiﬁcations
(Supplemental Table 1) (Tiller et al., 2009; Seidl et al., 1997). The
reactions were overlaid with 5 mL of sealing solution (Advalytix AG,
Munich, Germany), and ampliﬁcation was performed on an
AmpliSpeed slide cycler (Beckman Coulter, Houston, TX) as fol-
lows: 58 1C for 30 min, 93 1C for 10 min, 40 cycles of 93 1C for 45 s/
54 1C for 1 min/72 1C for 90 s and a ﬁnal incubation at 72 1C for
10 min. This initial reaction was transferred to a 96-well PCR plate
and diluted to a ﬁnal volume of 10 mL with RNase free water to
serve as a template for subsequent reactions. In total, 1 mL of the
1st round reaction was used as a template for a semi-nested (IgH)
and nested (IgK) reactions. The PCR was performed in 25 mL
reactions as follows: 94 1C for 5 min, 35 cycles of 93 1C for 45 s/
55 1C (IgH) or 45 1C (IgK) for 1 min/72 1C for 1.5 min and a ﬁnal
incubation at 72 1C for 10 min. Ampliﬁcation products were
screened by agarose gel electrophoresis, and positive amplicons
were sequenced for identiﬁcation of germline variable and joining
gene usage by the International ImMunoGeneTics information
system (IMGT) (Lefranc et al., 2009). Second-round reactions were
then repeated using 1 mL of the 1st round template and targeted,
gene-speciﬁc, V and J primers incorporating restriction sites for
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directional cloning into pFUSE2ss-CLIg-hG1 and pFUSE2ss-CLIg-hk
expression vectors (InvivoGen, San Diego, CA). EcoRI and BsiWI
were used for IgH and EcoRI and NheI for IgK ligations, respec-
tively. TOPO cloning was used as an alternative strategy for Ig's
with internal restriction sites.
Recombinant monoclonal antibody production and quantiﬁcation
293T cells in T160 ﬂasks at 80% conﬂuency were washed to
remove serum IgG, and covered with OPTIMEM (Invitrogen, Carlsbad,
CA) without serum. IgH and IgK constructs were co-transfected using
Lipofectamine 2000 (Invitrogen) according to the manufacturer's
instructions. The cell culture supernatants were harvested up to
10 days post-transfection and concentrated using Amicon Ultra-30
Centrifugal Filter Unit (Millipore, Billerica, MA). The concentration
of each recombinant monoclonal antibody (rmAb) was determined
by ELISA, and all the samples were normalized to a 25 mg/mL
working stock.
ELISA
Costar Hi Bind plates (Corning Inc., Tewksbury, MA) were coated
overnight with TIV or the individual monovalent inactivated virus
constituents at 4 1C. For 2011/12 TIV, 3 mg/ml of total HAwas adsorbed,
and 1 mg/ml total HA was adsorbed for the individual vaccine
constituents. For recHA, 1 mg/ml of respective protein was absorbed.
The plates were blocked for 1 h with PBS/0.1% Tween20 (PBST)
containing 1.5% BSA (blocking buffer) for 1 h at room temperature.
All rmAb were serially titrated in blocking buffer and allowed to
incubate for 1 h at room temperature. After three PBST washes, the
wells were probed with goat anti-human (H&L)–HRP (Thermo Scien-
tiﬁc) for 1 h at room temperature. The plates were washed three times
with PBST, and the signal was developed with 1 step™ Turbo TMB-
ELISA reagent (Thermo Scientiﬁc). The reactions were stopped with
1 N sulfuric acid, and the absorbance was read at 450 nm.
Hemagglutination inhibition assay
The indicated rmAb were tested for reactivity with the follow-
ing BPL-inactivated virus antigens: H1N1 A/California/07/2009
NYMC X-179A (FR-187), H3N2 A/Victoria/210/2009 X-187 (FR-
644) and B/Brisbane/60/2008 (FR-47) (IRR), by hemagglutination
(HI) assay as previously described (World Health Organization,
2011) using four hemagglutinating units (HAU) of antigen and 0.5%
turkey red blood cells.
BioLayer interferometry
The binding of each rmAb to CA/07 was analyzed by BioLayer
interferometry (BLI) on an Octet Red instrument (Fortebio, Inc.,
Menlo Park, CA) according to the manufacturer's instructions.
The CA/07(H1pdm) recHA protein (Chen et al., 2011) was diluted
to 75 mg/ml in kinetics buffer (KB; PBS containing 0.02% Tween 20,
0.005% sodium azide and 100 mg/ml bovine serum albumin,
purchased from Fortebio as 10 stock) and were coupled to
ofﬂine (prior to running assay) anti-Penta-His biosensors using a
Sidekick instrument (Fortebio). A two-fold dilution series (25–
0.391 mg/ml) for each rmAb in KB was prepared and analyzed,
including a commercial anti-A/California/06/2009 (H1N1pdm09)
mAb (Immune Technology Corp., CA) as a control. The data were
analyzed using the system software and exported as a Microsoft
Excel ﬁle for analysis and presentation in other software packages.
Alignments and phylogenetic trees
CDR3 regions were aligned using MUSCLE (Edgar, 2004) and
a maximum likelihood tree was generated using MEGA5 (Tamura
et al., 2011).
Estimates of germline diversity
To estimate the diversity of the germline population from
which our samples of anti-HA heavy and light chains were drawn,
we used the methods of Burnham and Overton (1978, 1979), Chao
(1984), Chao and Lee (1992), Chao and Bunge (2002), Wang and
Lindsay (2005), and Wang (2010), as implemented in the R module
SPECIES (Wang, 2011).
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